ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Construction In Progress: HK$0.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01541 ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
6 GF Score
Price HK$3.72
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress?

ImmuneOnco Biopharmaceuticals (Shanghai) HKSE:01541 +6.29% 6 Construction In Progress is HK$0.4 Mil as of Dec. 2025. GuruFocus rates HKSE:01541 with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

ImmuneOnco Biopharmaceuticals (Shanghai)'s quarterly construction in progress declined from Dec. 2024 (HK$29.3 Mil) to Jun. 2025 (HK$0.0 Mil) but then increased from Jun. 2025 (HK$0.0 Mil) to Dec. 2025 (HK$0.4 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai)'s annual construction in progress declined from Dec. 2023 (HK$36.1 Mil) to Dec. 2024 (HK$29.3 Mil) and declined from Dec. 2024 (HK$29.3 Mil) to Dec. 2025 (HK$0.4 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress Historical Data

* Premium members only.

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
20.28 36.08 36.06 29.25 0.39

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only 36.06 0.00 29.25 0.00 0.39
HKSE:01541
6GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$0.4 Mil mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a Construction In Progress of HK$0.4 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s Construction In Progress too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Construction In Progress is HK$0.4 Mil. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s Construction In Progress compare to VRTX and REGN?
ImmuneOnco Biopharmaceuticals (Shanghai)'s Construction In Progress of HK$0.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current Construction In Progress is HK$0.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a current Construction In Progress of HK$0.4 Mil. The current Construction In Progress is HK$0.4 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541), the current Construction In Progress is HK$0.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score

Get the complete analysis for HKSE:01541

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.72
Price